Intestinal dysbiosis compromises alveolar macrophage immunity to Mycobacterium tuberculosis. 2019

Nargis Khan, and Laura Mendonca, and Achal Dhariwal, and Ghislaine Fontes, and Dick Menzies, and Jianguo Xia, and Maziar Divangahi, and Irah L King
Meakins-Christie Laboratories, Department of Medicine, Department of Pathology, McGill University Health Centre, Montreal, QC, H4A 3J1, Canada.

Current treatments for tuberculosis (TB) are effective in controlling Mycobacterium tuberculosis (Mtb) growth, yet have significant side effects and do not prevent reinfection. Therefore, it is critical to understand why our host defense system is unable to generate permanent immunity to Mtb despite prolonged anti-tuberculosis therapy (ATT). Here, we demonstrate that treatment of mice with the most widely used anti-TB drugs, rifampicin (RIF) or isoniazid (INH) and pyrazinamide (PYZ), significantly altered the composition of the gut microbiota. Unexpectedly, treatment of mice with the pro-Mtb drugs INH and PYZ, but not RIF, prior to Mtb infection resulted in an increased bacterial burden, an effect that was reversible by fecal transplantation from untreated animals. Mechanistically, susceptibility of INH/PYZ-treated mice was associated with impaired metabolism of alveolar macrophages and defective bactericidal activity. Collectively, these data indicate that dysbiosis induced by ATT administered to millions of individuals worldwide may have adverse effects on the anti-Mtb response of alveolar macrophages.

UI MeSH Term Description Entries
D007113 Immunity, Innate The capacity of a normal organism to remain unaffected by microorganisms and their toxins. It results from the presence of naturally occurring ANTI-INFECTIVE AGENTS, constitutional factors such as BODY TEMPERATURE and immediate acting immune cells such as NATURAL KILLER CELLS. Immunity, Native,Immunity, Natural,Immunity, Non-Specific,Resistance, Natural,Innate Immune Response,Innate Immunity,Immune Response, Innate,Immune Responses, Innate,Immunity, Non Specific,Innate Immune Responses,Native Immunity,Natural Immunity,Natural Resistance,Non-Specific Immunity
D007538 Isoniazid Antibacterial agent used primarily as a tuberculostatic. It remains the treatment of choice for tuberculosis. Isonicotinic Acid Hydrazide,Ftivazide,Isonex,Isonicotinic Acid Vanillylidenehydrazide,Phthivazid,Phthivazide,Tubazide,Acid Vanillylidenehydrazide, Isonicotinic,Hydrazide, Isonicotinic Acid,Vanillylidenehydrazide, Isonicotinic Acid
D008810 Mice, Inbred C57BL One of the first INBRED MOUSE STRAINS to be sequenced. This strain is commonly used as genetic background for transgenic mouse models. Refractory to many tumors, this strain is also preferred model for studying role of genetic variations in development of diseases. Mice, C57BL,Mouse, C57BL,Mouse, Inbred C57BL,C57BL Mice,C57BL Mice, Inbred,C57BL Mouse,C57BL Mouse, Inbred,Inbred C57BL Mice,Inbred C57BL Mouse
D009169 Mycobacterium tuberculosis A species of gram-positive, aerobic bacteria that produces TUBERCULOSIS in humans, other primates, CATTLE; DOGS; and some other animals which have contact with humans. Growth tends to be in serpentine, cordlike masses in which the bacilli show a parallel orientation. Mycobacterium tuberculosis H37Rv
D011718 Pyrazinamide A pyrazine that is used therapeutically as an antitubercular agent. Tisamid
D004195 Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases. Animal Disease Model,Animal Disease Models,Disease Model, Animal
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000069196 Gastrointestinal Microbiome All of the microbial organisms that naturally exist within the GASTROINTESTINAL TRACT. Enteric Bacteria,Gastric Microbiome,Gastrointestinal Flora,Gastrointestinal Microbial Community,Gastrointestinal Microbiota,Gastrointestinal Microflora,Gut Flora,Gut Microbiome,Gut Microbiota,Gut Microflora,Intestinal Flora,Intestinal Microbiome,Intestinal Microbiota,Intestinal Microflora,Bacteria, Enteric,Flora, Gastrointestinal,Flora, Gut,Flora, Intestinal,Gastric Microbiomes,Gastrointestinal Microbial Communities,Gastrointestinal Microbiomes,Gastrointestinal Microbiotas,Gut Microbiomes,Gut Microbiotas,Intestinal Microbiomes,Intestinal Microbiotas,Microbial Community, Gastrointestinal,Microbiome, Gastric,Microbiome, Gastrointestinal,Microbiome, Gut,Microbiome, Intestinal,Microbiota, Gastrointestinal,Microbiota, Gut,Microbiota, Intestinal,Microflora, Gastrointestinal,Microflora, Gut,Microflora, Intestinal
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000904 Antibiotics, Antitubercular Substances obtained from various species of microorganisms that are, alone or in combination with other agents, of use in treating various forms of tuberculosis; most of these agents are merely bacteriostatic, induce resistance in the organisms, and may be toxic. Antitubercular Antibiotics

Related Publications

Nargis Khan, and Laura Mendonca, and Achal Dhariwal, and Ghislaine Fontes, and Dick Menzies, and Jianguo Xia, and Maziar Divangahi, and Irah L King
June 2024, Journal of immunology (Baltimore, Md. : 1950),
Nargis Khan, and Laura Mendonca, and Achal Dhariwal, and Ghislaine Fontes, and Dick Menzies, and Jianguo Xia, and Maziar Divangahi, and Irah L King
January 1997, Infection and immunity,
Nargis Khan, and Laura Mendonca, and Achal Dhariwal, and Ghislaine Fontes, and Dick Menzies, and Jianguo Xia, and Maziar Divangahi, and Irah L King
April 2009, American journal of respiratory cell and molecular biology,
Nargis Khan, and Laura Mendonca, and Achal Dhariwal, and Ghislaine Fontes, and Dick Menzies, and Jianguo Xia, and Maziar Divangahi, and Irah L King
October 1982, Pneumonologia polska,
Nargis Khan, and Laura Mendonca, and Achal Dhariwal, and Ghislaine Fontes, and Dick Menzies, and Jianguo Xia, and Maziar Divangahi, and Irah L King
January 2023, Current molecular medicine,
Nargis Khan, and Laura Mendonca, and Achal Dhariwal, and Ghislaine Fontes, and Dick Menzies, and Jianguo Xia, and Maziar Divangahi, and Irah L King
January 2003, Advances in experimental medicine and biology,
Nargis Khan, and Laura Mendonca, and Achal Dhariwal, and Ghislaine Fontes, and Dick Menzies, and Jianguo Xia, and Maziar Divangahi, and Irah L King
April 2002, Clinical microbiology reviews,
Nargis Khan, and Laura Mendonca, and Achal Dhariwal, and Ghislaine Fontes, and Dick Menzies, and Jianguo Xia, and Maziar Divangahi, and Irah L King
November 2019, International journal of molecular sciences,
Nargis Khan, and Laura Mendonca, and Achal Dhariwal, and Ghislaine Fontes, and Dick Menzies, and Jianguo Xia, and Maziar Divangahi, and Irah L King
June 2023, Research square,
Nargis Khan, and Laura Mendonca, and Achal Dhariwal, and Ghislaine Fontes, and Dick Menzies, and Jianguo Xia, and Maziar Divangahi, and Irah L King
February 2004, Journal of mathematical biology,
Copied contents to your clipboard!